Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.

Revenue
+5.86%
EPS
−95.8%
Free cash flow
−21.4%
Total debt
−9.16%

Quarter to September 2026, against a year earlier

272.44 3.88 −1.40%
Market cap
$655.6B
P/E
41.3×
Fwd P/E
40.0×
Dividend yield
1.94%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
19.70 357.00 23.00 25.89 28.56 21.90 26.44 11.58 24.93 18.73
Piotroski F-Score
7 4 9 6 4 8 5 6 6 3
P/S ratio
4.41 4.90 4.24 4.70 5.02 5.72 5.85 4.76 3.92 5.29
Altman Z-Score
5.10 4.21 4.27 4.31 3.99 4.34 4.25 4.59 4.01 4.78
Altman Z″-Score (non-manufacturers)
6.39 4.09 4.43 4.08 3.69 4.21 3.67 4.69 4.41 4.71
P/FCF ratio
18.87 19.11 15.92 16.64 20.22 22.00 26.39 21.78 16.97 24.40
Beneish M-Score
(2.51) (2.80) (2.68) (2.69) (2.79) (2.54) (2.65) (2.71) (2.75) (2.26)
P/Operating CF
47.66 61.39 55.42 60.31 49.66 78.55 87.44 51.54 49.86 68.16
Dividend Safety Score
— — — — — — — — — 78
P/B ratio
4.36 6.23 5.79 6.49 6.55 6.08 6.09 5.89 4.87 6.11
EV/Sales
4.14 5.06 4.34 4.79 5.11 5.70 5.91 4.79 3.99 5.49
EV/EBITDA
12.07 15.72 13.34 15.71 17.55 16.74 17.43 16.61 13.57 12.29
EV/FCF
17.71 19.75 16.29 16.95 20.58 21.92 26.65 21.94 17.27 25.35
Current Ratio
2.47 1.41 1.47 1.26 1.21 1.35 0.99 1.16 1.11 1.03
Net Debt/EBITDA
(0.79) 0.50 0.30 0.29 0.31 (0.06) 0.17 0.12 0.23 0.46
Debt/Equity
0.32 0.51 0.46 0.45 0.52 0.41 0.35 0.38 0.43 0.48
ROE
23.60% 1.99% 25.51% 25.36% 23.97% 30.41% 23.79% 48.29% 20.06% 35.03%
ROA
12.05% 0.87% 9.86% 9.73% 8.85% 11.70% 9.71% 19.81% 8.09% 14.13%
ROIC
24.29% 15.23% 16.60% 16.24% 14.58% 16.56% 14.86% 13.12% 13.44% 20.19%
Return on Tangible Assets
30.26% 4.40% 48.05% 56.06% 53.49% 60.14% 102.67% 129.66% 53.91% 108.66%
Average Days of Receivables
59.40 64.41 63.08 64.41 60.00 70.84 64.06 63.75 60.99 66.57
Earnings Yield
5.08% 0.28% 4.35% 3.86% 3.50% 4.57% 3.78% 8.63% 4.01% 5.34%
Free Cash Flow Yield
5.30% 5.23% 6.28% 6.01% 4.95% 4.55% 3.79% 4.59% 5.89% 4.10%
Free Cash Flow per Share
6.14 7.28 8.11 8.76 7.78 7.78 6.75 7.34 8.52 8.48
Book value per Share
25.73 22.35 22.28 22.48 24.03 28.12 29.26 27.15 29.70 33.87
Free Cash Flow
16,808.00 19,609.00 21,734.00 23,183.00 20,494.00 20,469.00 17,728.00 18,606.00 20,517.00 20,418.00
EV/EBIT
14.24 20.39 18.05 21.83 25.09 23.11 23.47 23.88 18.87 14.95
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026